Combination therapy for cancer: Phototherapy and HDAC inhibition

Abstract

Cutaneous T-cell lymphomas (CTCLs) are rare extranodal non-Hodgkin's characterised by pleomorphic skin lesions and distinct T-cell markers. The annual incidence of these non-Hodgkin's lymphomas are approximately 0.2-0.8/100,000 and mycosis fungoides (MF) or its leukemic variant, Sézary syndrome (SS), account for the majority of cases. CTCL is a relatively benign disease in its early stages, but survival rates decrease significantly as it progresses. As curative therapy remains elusive, the goal of therapy is preventing or slowing progression from early stages while minimising long-term toxicity associated with the treatments. Early-stage CTCL can often be controlled with skin-directed therap..